This webinar aims to introduce the use of various tools to elucidate transporter function and consequently, in vivo exposure to transporter substrates. This includes the use of proteomics to inform an efflux ratio-relative expression factor enabling prediction of fetal exposure across the placenta, a novel metabolomics approach to identify biomarkers of renal OAT1/3 and MRP2/4 and lastly, a case study highlighting the importance of elucidating both the pharmacokinetics and pharmacodynamics of a P-gp substrate in determining its efficacy as CNS drug. The present webinar also aims to recognize graduate students and postdoctoral fellows from academia who carried out transporter-related research and presented their work in the form of a poster in 2023 North American ISSX annual meeting.

In this webinar we will discuss efforts for improving the global underrepresentation of African genetics in science. We will further explore the current landscape and challenges in realizing an African hepatic modeling platform - with a specific focus on the development of hiPSC models that can better recapitulate hepatic function.

Selective inhibitors of drug metabolizing enzymes are critical for reaction phenotyping to characterize clearance pathways. New selective inhibitors have been identified to enable more effective understanding of mechanisms involved in metabolism and drug-drug interactions. Learning the characteristics of these new selective inhibitors will allow researchers to apply them readily to characterize new drug candidates.

This webinar is intended to highlight and discuss: The Process of Drug Discovery to Clinic.

This symposium is intended to provide perspectives on the impact that the ICH M12 guideline will have on the in vitro DDI studies required for drug development.

This webinar will highlight how primary human cells play a key role in the performance of Liver Tissue Chips, which are at the forefront of drug development technology. The Liver Tissue Chip, which utilizes primary cells such as human hepatocytes and non-parenchymal cells, represents a significant advancement in the field, offering a promising tool for predicting pharmacokinetic profiles, toxicodynamic assessment and drug safety evaluation in alignment with human physiology.

This webinar is intended to discuss a prodrug approach to target tumors. Developing tumor targeting prodrugs is highly challenging. There are not many successful examples in the field. Effective screening strategies are much needed to enable identification of successful prodrug candidates. This is a great example to spark some new ideas in the field. The enzymatic processes for prodrug cleavage are unique and the successful screening strategy is highly educational for scientists in the field.